Abstract
Purpose
Anticoagulation is part of the daily routine of intensive care physicians. As the possibilities of pharmacological anticoagulation are becoming more numerous and diverse, intensive care physicians have to be familiar with indications, contraindications, dosing, and reversal of many different substances. This paper presents an overview of the substance group of direct thrombin inhibitors (DTI) indicated for alternative anticoagulation in intensive care medicine.
Methods
The review is a synopsis of scientific evidence, expert opinion, open forum commentary, and clinical feasibility data.
Results and conclusions
Due to their antithrombotic potential without direct activation of platelets, DTI could offer potential advantages over heparins and vitamin K antagonists in critically ill patients, especially regarding heparin-induced thrombocytopenia. Because of multiple organ dysfunction, organ failure, and comedications, simple extrapolation of results of medical to critically ill patients is not permissible. The fine line between thrombosis and bleeding in intensive care patients requires cautious dosing and close drug monitoring. Studies dealing with DTI in the intensive care setting are of utmost clinical interest.
Similar content being viewed by others
References
Oliveira GB, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Ohman EM, Granger CB, Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators (2008) Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 168:94–102
Bates S, Weitz J (2000) The mechanisms of action of thrombin inhibitors. J Invasive Cardiol 12:27F–32F
Weitz JI (2003) A novel approach to thrombin inhibition. Thromb Res 109(Suppl 1):S17–S22
Kozek-Langenecker S, Mohammad S, Masaki T (2000) Effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. Anesth Analg 90:808–812
Xiao Z, Theroux P (1998) Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97:251–256
Sarich T, Woltz M, Eriksson U (2003) Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol 41:557–564
Hoppensteadt D, Jeske W, Walenga JM, Bick RL, Fareed J (2008) The anti-inflammatory effects of argatroban can be differentiated from other direct thrombin inhibitors: experimental and clinical observations. Semin Thromb Haemost 34:97–102
Selleng K, Greinacher A (2005) Heparin-induzierte Thrombozytopenie in der Intensivmedizin. Intensivmedizin Update 1:1–16
Selleng K, Selleng S, Greinacher A (2008) Heparin-induced thrombocytopenia in intensive care patients. Semin Thromb Hemost 34:425–438
Warkentin T, Greinacher A, Koster A, Lincoff AM (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edn). Chest 133:340S–380S
Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG (2003) Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 23:745–753
Muslimani A, Ricaurte B, Daw H (2007) Immune heparin-induced thrombocytopenia resulting from preceding exposure to heparin catheter flushes. Am J Haematol 82:652–655
Warkentin T, Hayward C, Boshkowv L (1994) Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84:3691–3693
Greinacher A, Vögel H, Janssen U (1999) Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 100:587–590
Lewis B, Hursting M (2004) Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin T, Greinacher A (eds) Heparin-induced thrombocytopenia. Marcel Dekker, New York, pp 437–474
Lubenow N, Eichler P, Lietz T (2004) Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 104:3072–3077
Metnitz PG, Krenn CG, Steltzer H, Lang T, Ploder J, Lenz K, Le Gall JR, Druml W (2002) Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 30:2051–2058
Kozek-Langenecker S (2002) Hämofiltration und Blutgerinnung. Anaesthesist 51:210–217
Salmon J, Cardigan R, Mackie I, Cohen SL, Machin S, Singer M (1997) Continuous venovenous hemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways. Intensive Care Med 23:38–43
Cardigan R, McGloin H, Mackie I, Machin SJ, Singer M (1999) Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney Int 55:1568–1574
LaMonte M, Brown P, Hursting M (2005) Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor. Expert Rev Cardiovasc Ther 3:31–41
Davenport A (2007) Anticoagulation options for patients with heparin-induced thrombocytopenia requiring renal support in the intensive care unit. In: Ronco C, Bellomo R, Kellum J (eds) Acute kidney injury, vol 156. Karger, Basel, pp 259–266
Rydel T, Ravichandran K, Tulinsky A (1990) The structure of a complex of recombinant hirudin and human a-thrombin. Science 249:277–280
Vanholder R, Camez A, Veys N (1997) Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost 77:650–655
Eichler P, Friesen H, Lubenow N (2000) Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 96:2373–2378
Greinacher A, Lubenow N, Eichler P (2003) Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108:2062–2065
Veach S, Franks A, Allan M (2007) Severe anaphylactic reaction after repeated intermittent exposure to lepirudin. Pharmacotherapy 27:760–765
Fenyvesi T, Jorg I, Harenberg J (2002) Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 28:361–368
Wenzel C, Stoiser B, Locker G, Laczika K, Quehenberger P, Kapiotis S, Frass M, Pabinger I, Knöbl P (2002) Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med 30:763–770
Clarke R, Mayo G, Fitzgerald G, Fitzgerald D (1991) Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 83:1510–1518
Francis JL, Hursting MJ (2005) Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul Fibrinolysis 16:251–257
Pötsch B, Madlener K (2004) Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Warkentin T, Greinacher A (eds) Heparin-induced thrombocytopenia. Marcel Dekker, New York, pp 531–532
Moser M, Ruef J, Peter K (2001) Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity. J Thromb Thrombolysis 12:165–169
Callas D, Hoppensteadt D, Iqbal O, Fareed J (1996) Ecarin clotting time (ECT) is a reliable method for the monitoring of hirudins, argatroban, efegatran and related drugs in therapeutic and cardiovascular indications. Ann Haematol 1:A58 (abstract)
Callas D, Fareed J (1996) Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method. Thromb Res 83:463–468
Lange U, Nowak G, Bucha E (2003) Ecarin chromogenic assay—a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb 33:184–191
Lindhoff-Last E, Piechotta G, Rabe F, Bauersachs R (2000) Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res 100:55–60
Lubenow N, Eichler P, Lietz T, Greinacher A, Hit Investigators Group (2005) Lepirudin in patients with heparin-induced thrombocytopenia—results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 3:2428–2436
Hacquard M, de Maistre E, Lecompte T (2005) Lepirudin: is the approved dosing schedule too high? J Thromb Haemost 3:2593–2596
Greinacher A (2004) Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy. Expert Rev Cardiovasc Ther 2:339–357
Greinacher A, Eichler P, Lubenow N (2000) Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96:846–851
Kassimatis T, Apostolou T, Theodoridis T (2006) The use of lepirudin in haemodialysis complicated with heparin-induced thrombocytopenia type II (HIT II)—dosage monitoring. Nephrol Dial Transplant 21:3341–3342
Dager W, White R (2001) Use of lepirudin in patients with heparin-induced thrombocytopenia and renal failure requiring hemodialysis. Ann Pharmacother 35:885–890
Fischer K, van de Loo A, Bohler J (1999) Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl 72:S46–S50
Chuang P, Parikh C, Reilly R (2001) A case review: anticoagulation in hemodialysis patients with heparin-induced thrombocytopenia. Am J Nephrol 21:226–231
Kozek-Langenecker S, Fries D, Gütl M (2005) Locoregional anesthesia and coagulation inhibitors. Recommendations of the Task Force on Perioperative Coagulation of the Austrian Society for Anesthesiology and Intensive Care Medicine. Anaesthesist 54:476–484
http://www.oegari.at/dateiarchiv/116/Regionalanaesthesia%20engl.pdf. Accessed 24 Feb 2010
Ibbotson SH, Grant PJ, Kerry R (1991) The influence of infusions of 1-desamino-8-d-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro. Thromb Haemost 65:64–66
Amin DM, Mant TG, Walker SM (1997) Effect of a 15-minute infusion of DDAVP on the pharmacokinetics and pharmacodynamics of REVASC during a four-hour intravenous infusion in healthy male volunteers. Thromb Haemost 77:127–132
Bove CM, Casey B, Marder VJ (1996) DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost 75:471–475
Butler KD, Dolan SL, Talbot MD, Wallis RB (1993) Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat. Blood Coagul Fibrinolysis 4:459–464
Irani MS, White HJ Jr, Sexon RG (1995) Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate. Am J Cardiol 75:422–423
Fareed J, Walenga JM, Pifarre R (1991) Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin. Haemostasis 21(Suppl 1):64–72
Irani M, White H, Sexon G (1995) Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate. Am J Cardiol 75:422–423
Diehl K, Romisch J, Hein B (1995) Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. Haemostasis 25:182–192
Novak G, Bucha E (1995) Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin. Thromb Res 80:317–325
Maraganore J, MBourdon P, Jablonski J (1990) Design and characterization of Hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29:7095–7101
Parry M, Maraganore J, Stone S (1994) Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry 33:14807–14814
Robson R, White H, Aylward P, Frampton C (2002) Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender. Clin Pharmacol Ther 71:433–439
Chew D, Bhatt D, Kimball W (2003) Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 92:919–923
Welsby I, Stafford-Smith M (2004) Monitoring direct thrombin inhibitors: time for standardization (comment). Anesthesiology 101:1048–1049
Casserly I, Kereiakes D, Gray W (2004) Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. Thromb Res 113:115–121
Cho L, Kottke-Marchant K, Lincoff A (2003) Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentration. Am J Cardiol 91:1110–1112
Chamberlin J, Lewis B, Leya F (1995) Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol 11:511–514
Francis JL, Drexler A, Gwyn G (2003) Bivalirudin, a direct thrombin inhibitor, is a safe and effective treatment for heparin-induced thrombocytopenia (abstract). Blood (Suppl) 102:164a
Kiser T, Fish D (2006) Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 26:452–460
Bartholomew J (2004) Bivaliruding for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds) Heparin-induced thrombocytopenia, vol 3. Marcel Dekker, New York, pp 475–507
Kiser TH, Burch JC, Klem PM, Hassell KL (2008) Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy 28:1115–1124
Young G, Yonekawa K, Nakagawa P (2007) Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux argatroban, and bivalirudin ex vivo as measured using thrombelastography. Blood Coagul Fibrinolysis 18:547–553
Koster A, Chew DP, Gründel M (2003) An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg 96:1316–1319
Mann M, Tseng EE, Ratcliff M (2005) Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant 24:222–225
Hauptmann J, Sturzebecher J (1999) Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res 93:203–241
Berry C, Girardot C, Lecroffre C, Lunven C (1994) Effect of synthetic thrombin inhibitor argatroban on fibrin- and clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 72:381–386
Swan S, Hursting M (2000) The pharmacokinetics and pharmacodynamics of argatroban: effect of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20:318–329
Walenga J, Ahmad S, Hoppensteadt D (2002) Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 105:401–405
Warkentin TE, Greinacher A, Craven S, Dewar L, Sheppard JA, Ofosu FA (2005) Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 94:958–964
Molinaro RJ, Szlam F, Levy JH, Fantz CR, Tanaka KA (2008) Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin. Anesthesiology 109:160–161
Engström M, Rundgren M, Schött U (2010) An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and activated partial thromboplastin time. Acta Anaesthesiol Scand 54:86–91
Harder S, Graff J, Klinkhardt U (2004) Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and ecarin clotting time. Thromb Haemost 91:1137–1145
Lewis B, Wallis D, Berkowitz S (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838–1843
Lewis B, Wallis D, Leya F (2003) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163:1849–1856
Williamson D, Boulanger I, Tardif M (2004) Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 24:409–414
Dyke P, Russo P, Mureebe L (2005) Argatroban for anticoagulation during cardiopulmonary bypass in an infant. Pediat Anesthesia 15:328–333
Risch L, Huber AR, Schmugge M (2006) Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. Thromb Res 118:123–135
Beiderlinden M, Treschan T, Görlinger K, Peters J (2007) Argatroban anticoagulation in critically ill patients. Ann Pharmacother 41:749–754
Beiderlinden M, Treschan T, Görlinger K, Peters J (2007) Argatroban in extracorporeal membrane oxygenation. Artif Organs 31:461–465
Koster A, Hentschel T, Groman T (2007) Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery. J Thorac Cardiovasc Surg 133:1376–1377
Reddy B, Grossman E, Trevino S (2005) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother 39:1601–1605
Ota K, Akizawa T, hirasawa Y (2003) Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant 18:1623–1630
Tang I, Cox D, Patel K (2005) Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 39:231–236
Murray P, Hursting M (2006) Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis. Ren Fail 28:537–539
Murray P, Reddy B, Grossman E (2004) A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 66:2446–2453
Krieger D, Geisen U, Is A, Fischer K (2007) Hemodialyser membranes allow for removal of argatroban. J Thromb Haemost 5(Suppl 1):P-S-669
Yee AJ, Kuter DJ (2006) Successful recovery after an overdose of argatroban. Ann Pharmacother 40:336–339
Murray PT, Reddy BV, Grossman EJ (2004) A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 66:2446–2453
Stangier J, Clemens A (2009) Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. Aug 19 [Epub ahead of print]
Alban S (2008) Pharmacology of heparins and direct anticoagulants. Haemostaseologie 28:400–420
Direct Thrombin Inhibitor Trialists’ Collaborative Group (2002) Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data. Lancet 359:294–302
Sinnaeve PR, Simes J, Yusuf S, Garg J, Mehta S, Eikelboom J, Bittl JA, Serruys P, Topol EJ, Granger CB (2005) Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. Eur Heart J 26:2396–2403
Lewis BE, Hursting MJ (2007) Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 5:57–68
Taketomi T, Szlam F, Vinten-Johansen J (2007) Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors. Blood Coagul Fibrinolysis 18:761–767
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schaden, E., Kozek-Langenecker, S.A. Direct thrombin inhibitors: pharmacology and application in intensive care medicine. Intensive Care Med 36, 1127–1137 (2010). https://doi.org/10.1007/s00134-010-1888-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-010-1888-3